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Introduction: Genomic studies of malignant pleural mesothelioma 
(MPM) have recently identified frequent mutations in the BRCA-
associated protein 1(BAP1) gene. In uveal melanoma and clear cell 
renal cell carcinoma, BAP1 mutations are associated with poor out-
comes but their clinical significance in MPM is unknown. We there-
fore undertook this study to define the characteristics of patients 
whose MPM tumors harbor somatic BAP1 mutation and to examine 
the relationship between BAP1 mutation and survival.
Methods: We reviewed the charts of 121 patients with MPM tumors 
diagnosed between 1991 and 2009 tested for BAP1 mutation, and 
extracted the following information: age at diagnosis, sex, histology, 
stage, smoking status, asbestos exposure, family or personal history 
of malignancy, and treatment including surgery, chemotherapy, and 
radiation as well as survival status.
Results: Twenty-four of the 121 tumors (20%) harbored somatic 
BAP1 mutations. The percentage of current or former smokers 
among cases with BAP1 mutations was significantly higher than in 
BAP1 wild-type cases, (75% versus 42%; p = 0.006). However, the 
types of nucleotide substitutions in BAP1 did not suggest that this 
association was because of a causative role of smoking in BAP1 
mutations. No other clinical feature was significantly different 
among those with and without BAP1 mutations in their MPM. There 
was also no difference in survival according to somatic BAP1 muta-
tion status.
Conclusion: There is no apparent distinct clinical phenotype for 
MPM with somatic BAP1 mutation. The significance of the more fre-
quent history of smoking among patients with BAP1-mutated MPM 
warrants further study.
Key Words: Mesothelioma, BRCA-associated protein 1, Novel 
therapeutics.
(J Thorac Oncol. 2013;8: 1430-1433)
Despite aggressive multimodality therapy, malignant pleu-ral mesothelioma (MPM) remains almost universally 
fatal with a median overall survival (OS) of 9 to 18 months 
from the time of diagnosis. First-line chemotherapy with cis-
platin and pemetrexed improves survival by a few months but 
the benefit, if any, of additional chemotherapy is modest. To 
improve these poor outcomes, many novel agents are currently 
under investigation in clinical trials. Unfortunately, despite the 
activity of these agents in other malignancies, there has been 
little efficacy in MPM. In an effort to help develop more effec-
tive MPM-specific therapeutics, much effort has focused on 
identifying the key cancer genes driving MPM oncogenesis.
Although it has been known for many years that inac-
tivating mutations in neurofibromatosis 2 and deletions of 
p16 are common in MPM, another commonly mutated gene, 
BRCA-associated protein 1 (BAP1), was only recently iden-
tified.1 In the initial report, BAP1 mutations were identified 
in 23% of the MPM specimens. A variety of alterations were 
noted, including nonsense mutations, missense mutations, 
frameshifting indels, and mutations at or near splice sites. 
Loss of nuclear BAP1 protein expression was confirmed by 
immunohistochemistry in MPM with BAP1 mutation. No 
association was identified between BAP1 mutation and other 
commonly identified genetic alterations including p16 loss 
and neurofibromatosis 2 mutation and/or loss.
BAP1 is a 729 amino acid nuclear ubiquitin hydrolase 
with multiple functional domains and it has, therefore, been 
implicated in several cellular processes such as cell prolif-
eration, DNA repair response, and chromatin dynamics.2 
Specifically, an interaction between BAP1 and host cell factor 
1, which interacts with histone-modifying complexes during 
cell division, has been described.1 More recently, it has been 
shown that BAP1, through an interaction with additional sex 
like 1 (ASXL1) forms the polycomb group repressive deubiq-
uitinase complex, which affects stem cell pluripotency.3
Mutations in BAP1 have also been described in other 
cancers. In particular, BAP1 mutation is common in uveal 
melanoma (UM), the most frequent ocular tumor in white 
adults, where it is strongly associated with poor outcomes. 
About 50% of UMs will metastasize, at which point no effec-
tive treatment exists. A multigene expression profiling assay 
divides UMs into low- and high-metastatic risk with 84% 
of metastatic UM harboring BAP1 mutation compared with 
only 4% of low-risk cases.4 Likewise, in clear cell renal cell 
carcinoma, somatic BAP1 mutations are associated with 
higher-grade tumors and shorter cancer-specific survival.5 
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Furthermore, recent reports have described germline BAP1 
mutations in families predisposed to MPM and UM6 as well as 
atypical melanocytic tumors7 and renal cell carcinoma.8 These 
findings clearly suggest the existence of a new hereditary 
cancer predisposition syndrome, but the phenotype and pen-
etrance of germline BAP1 mutations remain unclear as does 
the role of gene–environment interactions in the development 
of these tumors.
Although BAP1 mutation is considered a crucial event 
in the progression of UM,4 the clinical impact of BAP1 muta-
tion in MPM remains unknown. Therefore, the purpose of 
this study was to characterize the clinical features of MPM 
patients whose tumors harbor BAP1 mutations. Additionally, 
we examined the relationship between BAP1 mutation and 
survival.
MATERIALS AND METHODS
With the approval of the Memorial Sloan-Kettering 
Cancer Center Institutional Review Board, the clinical records 
of 121 patients whose MPM tumors had been tested for BAP1 
mutation by conventional Sanger sequencing were reviewed. 
Sanger sequencing was carried out by a commercial vendor 
on a high-throughput platform (Beckman Coulter Genomics, 
Brea, CA). Polymerase chain reaction and resequencing were 
performed to confirm candidate mutations. These 121 tumor 
specimens were collected over 18 years from 1991 to 2009. 
Samples were selected based on the availability of frozen 
tumor specimens that were collected as part of a surgical 
banking effort. Clinical features were extracted, including age 
at diagnosis, sex, histology, stage, smoking status, pack-years, 
asbestos exposure, family or personal history of malignancy, 
and treatment including surgery, chemotherapy, and radiation, 
as well as survival status.
The relationship between BAP1 mutation status and 
age, sex, histology, stage, smoking status, asbestos exposure, 
and family or personal history of malignancy was assessed 
using Fisher’s exact tests. To ensure that outcomes stratified 
by BAP1 mutation status were not confounded by differences 
in therapy, the relationship between BAP1 mutation status and 
surgery, chemotherapy, and radiation was also assessed using 
Fisher’s exact tests. OS was estimated using Kaplan–Meier 
method, with patients followed up from the time of diagnosis 
to death. Patients alive at the end of the study were censored at 
the time of the last available follow-up. The BAP1 mutant and 
BAP1 wild-type groups were compared with respect to OS, 
using the log-rank test.
RESULTS
Twenty-four of 121 MPM tumors harbored a somatic 
BAP1 mutation, giving a frequency of 20% (95% confi-
dence interval [CI], 13%–27%). Baseline characteristics of 
all patients included in this analysis are displayed in Table 1. 
The median age was 64 years (range, 33–81). Seventy per-
cent were men. Histology was distributed with 76% epitheli-
oid, 15% mixed, and 9% sarcomatoid. Stage at diagnosis was 
7% stage I, 26% stage II, 42% stage III, and 25% stage IV. 
Forty-nine percent of patients were former or current smokers 
with median pack-years of 26 whereas 40% reported known 
asbestos exposure. Treatment included extrapleural pneumo-
nectomy in 54%, pleurectomy/decortication in 36%, and no 
surgery in 10%. Fifty-six percent received chemotherapy and 
60% received radiation. A family history of mesothelioma 
was reported in 2% of patients and a family history of any 
cancer in 55%. Ten percent of patients had a personal history 
of cancer before the diagnosis of MPM. In addition, 8% of 
patients had a personal or family history of skin cancer.
As shown in Table 2, with univariate analysis there 
was no significant difference in age, sex, asbestos exposure, 
surgery, chemotherapy, radiation, family history of mesothe-
lioma, family history of cancer, and personal history of cancer 
among patients with BAP1 mutant and BAP1 wild-type MPM. 
However, a smoking history, either former or current, was more 
common among those with BAP1 mutant tumors, 75% versus 
42% (p = 0.006). There was no difference in pack-years among 
the smokers with respect to BAP1 mutation status. On the basis 
of this association, we reviewed the spectrum of nucleotide 
substitutions in BAP1-mutated cases for evidence of a causal 
link to smoking. Fourteen of the 24 mutations identified in 
BAP1 were point mutations. Among those 14 point mutations, 
only two represented classic smoking-associated nucleotide 
transversions (Supplementary Table 1, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A450).
TABLE 1.  Patient Characteristics
% (N = 121)
Age, median (range) 64 (33–81)
Sex
  Male 70 (85)
  Female 30 (36)
Histology
  Epithelioid 76 (92)
  Mixed 15 (18)
  Sarcomatoid 9 (11)
Stage
  I 7 (8)
  II 26 (32)
  III 42 (51)
  IV 25 (30)
Former and current smoking 49 (59)
Pack-years 26 (52)
Known asbestos exposure 40 (48)
Surgery
  EPP 54 (66)
  P/D 36 (43)
  None 10 (12)
Chemotherapy 56 (68)
Radiation 60 (73)
Family history of mesothelioma 2 (3)
Family history of cancer 55 (67)
Personal history of cancer 10 (12)
Personal or family history of skin cancer 8 (10)
EPP, extrapleural pneumonectomy; P/D, pleurectomy/decortication.
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There was no significant difference (p = 0.43) in the 
stage at presentation for BAP1 mutant versus wild-type dis-
ease (Fig. 1). Similarly, there was no difference (p = 0.28) 
in the distribution of histologies among BAP1 mutant versus 
wild-type disease (Fig. 2). No difference in OS was associ-
ated with BAP1 mutation status. Those with BAP1 mutant 
tumors had a median OS of 14.3 months (95% CI, 12.4–19.4) 
whereas those with BAP1 wild-type tumors had a median OS 
of 14.8 months (95% CI, 10.6–37.3), p = 0.81. Adjusted for 
stage, the p value remains nonsignificant (p = 0.77).
DISCUSSION
Twenty percent of MPM tumors harbor mutations in 
BAP1. We find that a smoking history is significantly more 
common in MPM patients whose tumors harbor a BAP1 muta-
tion. The biological significance of this observation is pres-
ently unclear. Perhaps, BAP1 mutation is a sequela of toxic 
exposure to smoking but the wide variety of mutations is not 
typical of tobacco smoke mutagenesis (only 2 of 24 mutations 
were G to T transversions, consistent with classic smoking-
associated changes). Alternatively, BAP1 somatic mutation 
could be an early event that might impair the response to 
carcinogenic damage inflicted by smoking in the develop-
ment of mesothelioma. Other clinical characteristics were 
similar among those with mutant and wild-type BAP1 MPM. 
Although another group reported that BAP1 mutated cases 
were more likely to be partly or entirely epithelioid, this differ-
ence was not statistically significant in our larger cohort.9 No 
difference in survival was observed. Similarly, although the 
initial report of BAP1 mutations in MPM found an association 
between older age and BAP1 mutation,1 such association is 
not confirmed in this larger series.
This analysis has some limitations. The retrospective 
nature of this project precluded thorough investigation of 
smoking status, asbestos exposure, personal history of malig-
nancy, and family history of mesothelioma and other malig-
nancies. Finally, as these specimens were obtained over an 
18-year period, changes in therapy could have obscured dif-
ferences in survival by BAP1 mutation status.
Since the initial reports of germline BAP1 mutations, 
numerous other neoplasms including meningiomas, renal 
cell carcinoma, lung cancer, breast cancer, ovarian cancer, 
pancreas cancer, and leukemia have been associated with 
BAP1 mutation.10–15 Although there is no apparent distinct 
phenotype for MPM with somatic BAP1 mutation, further 
study is needed to identify and characterize patients with 
germline BAP1 mutations. To help describe the spectrum 
of disease associated with germline BAP1 mutation, we 
have initiated a prospective clinical protocol for patients 
with MPM, UM, and choroidal nevus (a premalignant eye 
tumor). First, patients will provide samples to participate in 
an anonymous estimate of the prevalence of germline BAP1 
mutations. Additionally, patients whose tumors harbor BAP1 
TABLE 2.  Clinical Features of Patients with BAP1 Mutant 
Versus BAP1 Wild-Type MPM
BAP1  
Mutant % 
(n = 24)
BAP1  
Wild-Type % 
(n = 97) p
Sex (M/F) 79/21 68/32 0.33
Median age, yr 65 63 0.31
Asbestos exposure 54 46 1
Former and current  
smoking
75 42 0.006
Median pack-years 30 25 0.47
Surgery
  EPP 54 55 1
  P/D 38 35
  None 8 10
Chemotherapy 54 57 0.82
Radiation 71 58 0.35
Family history of 
mesothelioma
4 2 1
Family history of cancer 38 47 0.49
Personal history of cancer 8 8 0.46
EPP, extrapleural pneumonectomy; P/D, pleurectomy/decortication.
FIGURE 1.  The distribution of stage by plotted by BAP1 
mutation status. There is no observed difference (p = 0.43). 
WT, wild type.
FIGURE 2.  The distribution of malignant pleural mesothe-
lioma histology is plotted by BAP1 mutation status. There is 
no observed difference (p = 0.28). WT, wild type.
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mutation or who meet prespecified criteria will be offered 
identified germline BAP1 testing. Those patients identified 
as carrying germline BAP1 mutations will be asked to invite 
both potentially affected and unaffected family members for 
testing through our Clinical Genetics Service. We will also 
continue to explore the interaction of BAP1 mutation with 
other somatic mutations, environmental exposures, and sin-
gle-nucleotide polymorphisms. As with other malignancies, 
insights into the biology of MPM may help identify new, 
disease-specific therapeutic targets.
ACKNOWLEDGMENTS
Supported in part by the Mesothelioma Applied 
Research Foundation.
REFERENCES
 1. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is 
commonly inactivated by somatic mutations and 3p21.1 losses in malig-
nant pleural mesothelioma. Nat Genet 2011;43:668–672.
 2. Ladanyi M, Zauderer MG, Krug LM, et al. New strategies in pleu-
ral mesothelioma: BAP1 and NF2 as novel targets for therapeu-
tic development and risk assessment. Clin Cancer Res 2012;18: 
4485–4490.
 3. Scheuermann JC, de Ayala Alonso AG, Oktaba K, et al. Histone H2A 
deubiquitinase activity of the Polycomb repressive complex PR-DUB. 
Nature 2010;465:243–247.
 4. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 
in metastasizing uveal melanomas. Science 2010;330:1410–1413.
 5. Hakimi AA, Chen YB, Wren J, et al. Clinical and pathologic impact of 
select chromatin-modulating tumor suppressors in clear cell renal cell 
carcinoma. Eur Urol 2013;63:848–854.
 6. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to 
malignant mesothelioma. Nat Genet 2011;43:1022–1025.
 7. Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 
predispose to melanocytic tumors. Nat Genet 2011;43:1018–1021.
 8. Popova T, Hebert L, Jacquemin V, et al. Germline BAP1 mutations pre-
dispose to renal cell carcinomas. Am J Hum Genet May 14, 2013 [Epub 
ahead of print].
 9. Yoshikawa Y, Sato A, Tsujimura T, et al. Frequent inactivation of the 
BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 
2012;103:868–874.
 10. Abdel-Rahman MH, Pilarski R, Cebulla CM, et al. Germline BAP1 muta-
tion predisposes to uveal melanoma, lung adenocarcinoma, meningioma, 
and other cancers. J Med Genet 2011;48:856–859.
 11. Carbone M, Ferris LK, Baumann F, et al. BAP1 cancer syndrome: malig-
nant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J 
Transl Med 2012;10:179.
 12. Dey A, Seshasayee D, Noubade R, et al. Loss of the tumor suppressor 
BAP1 causes myeloid transformation. Science 2012;337:1541–1546.
 13. Fan LH, Tang LN, Yue L, Yang Y, Gao ZL, Shen Z. BAP1 is a good prog-
nostic factor in advanced non-small cell lung cancer. Clin Invest Med 
2012;35:E182–E189.
 14. Njauw CN, Kim I, Piris A, et al. Germline BAP1 inactivation is preferen-
tially associated with metastatic ocular melanoma and cutaneous-ocular 
melanoma families. PLoS One 2012;7:e35295.
 15. Wadt K, Choi J, Chung JY, et al. A cryptic BAP1 splice mutation in a 
family with uveal and cutaneous melanoma, and paraganglioma. Pigment 
Cell Melanoma Res 2012;25:815–818.
